Neumora Stock Hits Record Low on Depression Drug Study Failure

Zacks01-03

Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD). The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500145917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 22:14","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500145917","market":"us","top_or_hot":-1,"title":"Neumora Stock Hits Record Low on Depression Drug Study Failure","media":"Zacks","content":"<div>\n<p>Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD).\nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Stock Hits Record Low on Depression Drug Study Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Stock Hits Record Low on Depression Drug Study Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD).\nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSTL","symbol_name":"Castle Biosciences, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html","article_id":"2500145917","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500145917","pubTimestamp":1735913640,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale .The study also failed to show statistically significant improvement in the reduction of anhedonia , as assessed by the Snaith-Hamilton Pleasure Scale .The KOASTAL-1 study is one of the three late-stage studies in the KOASTAL program evaluating navacaprant in the MDD indication. Despite the study's failure, Neumora intends to continue the other two studies. In the meantime, management continues to further analyze the study results, as management claimed that the drug showed an efficacy signal in female patients.Following the news, shares of Neumora hit an all-time low of $1.83. The latest anno","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSTL":"Castle Biosciences, Inc.","CTMX":"CytomX","ABVC":"ABVC BioPharma, Inc.","NMRA":"Neumora Therapeutics, Inc.","SPRO":"Spero Therapeutics Inc.","BK4139":"生物科技","BK4007":"制药","BK4196":"保健护理服务"},"translate_title":"Neumora股价因抑郁症药物研究失败而创历史新低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1,"CTMX":1,"SPRO":1,"NMRA":0.9,"ABVC":0.81},"content_text":"Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD).\nThe phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).\nThe study also failed to show statistically significant improvement in the reduction of anhedonia (the inability to feel pleasure), as assessed by the Snaith-Hamilton Pleasure Scale (SHAPS).\nThe KOASTAL-1 study is one of the three late-stage studies in the KOASTAL program evaluating navacaprant in the MDD indication. Despite the study's failure, Neumora intends to continue the other two studies. In the meantime, management continues to further analyze the study results, as management claimed that the drug showed an efficacy signal in female patients.\nNMRA Stock Performance\nFollowing the news, shares of Neumora hit an all-time low of $1.83. The latest announcement failed to impress investors, who had high hopes for navacaprant based on data from a previously conducted mid-stage study.\nIn the past year, Neumora Therapeutics’ shares have plummeted 87.5% compared with the industry’s 13.6% decline.\nImage Source: Zacks Investment Research\n \nMore on NMRA’s KOASTAL-1 Study Results\nA total of 383 study participants were enrolled in the KOASTAL-1 study, who were randomized into two equal groups – one receiving navacaprant and the other receiving placebo.\nData from the study revealed that patients in both groups achieved the same scores on the MADRS scale, which was an average 12.5-point decrease in depression symptoms. MADRS is a metric showing the improvement of depressive symptoms in MDD patients compared with placebo after the treatment period. A higher MADRS score reflects greater depression severity.\nHowever, Neumora's reported results revealed a variation in response based on gender. Men who received navacaprant achieved an average 10.6-point decrease in depression symptoms, compared to an average 14-point decrease in women. When comparing these results against their respective placebo groups, the results favored the male patients – men who took the placebo experienced an average 13.8-point decrease compared to the average 11.4-point decrease observed in women.\nSome investors also raised concerns about a lack of explanation on Neumora’s part as to why navacaprant would perform better in women than in men. The SHAPS scale, which measures a person's ability to feel pleasure, also favored men. A higher total SHAPS score indicates higher levels of the current state of anhedonia.\nNMRA’s Zacks Rank\nNeumora Therapeutics currently carries a Zacks Rank #3 (Hold).\n\nNeumora Therapeutics, Inc. Price\n\nNeumora Therapeutics, Inc. price | Neumora Therapeutics, Inc. Quote\n\nKey Picks Among Biotech Stocks\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO. CSTL and SPRO sport a Zacks Rank #1 (Strong Buy) at present, and CTMX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nBottom-line estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past year, shares of Castle Biosciences have surged 34.9%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past year, Spero’s shares have lost 26.5%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 34.9% in the past year.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nNeumora Therapeutics, Inc. (NMRA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500145917"}